mercaptopurine and Substance-Withdrawal-Syndrome

mercaptopurine has been researched along with Substance-Withdrawal-Syndrome* in 3 studies

Reviews

1 review(s) available for mercaptopurine and Substance-Withdrawal-Syndrome

Article	Year
Can azathioprine 6-mercaptopurine treatment be withdrawn in patients with response in ulcerative colitis: what is the most appropriate time for this? The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2012, Volume: 23 Suppl 2 Topics: Azathioprine; Colitis, Ulcerative; Humans; Immunosuppressive Agents; Mercaptopurine; Substance Withdrawal Syndrome; Time Factors	2012

Article

Year

Can azathioprine 6-mercaptopurine treatment be withdrawn in patients with response in ulcerative colitis: what is the most appropriate time for this?

The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2012, Volume: 23 Suppl 2

Topics: Azathioprine; Colitis, Ulcerative; Humans; Immunosuppressive Agents; Mercaptopurine; Substance Withdrawal Syndrome; Time Factors

2012

Other Studies

2 other study(ies) available for mercaptopurine and Substance-Withdrawal-Syndrome

Article	Year
Unusual skin rash following withdrawal of oral 6-mercaptopurine in children with leukemia. Medical and pediatric oncology, 1987, Volume: 15, Issue:5 Sixteen episodes of a distinctive, papular rash occurred in eight patients following withdrawal of 6-mercaptopurine (6MP) and methotrexate (MTX) used as maintenance therapy for acute lymphoblastic leukemia (ALL). The rash also developed in one of the eight patients when only 6MP was discontinued. The eruption occurred mainly on the face, and in this site resembled the perioral dermatitis seen following withdrawal of topical fluorinated steroids. The rash generally began within 3 weeks of stopping 6MP and lasted 3 to 4 weeks. It failed to improve with the use of topical corticosteroid. We conclude that this rash is caused by the withdrawal of oral 6MP. Topics: Child; Face; Female; Humans; Leukemia, Lymphoid; Male; Mercaptopurine; Skin Diseases; Substance Withdrawal Syndrome	1987
Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet (London, England), 1975, Sep-20, Volume: 2, Issue:7934 In three patients with malignant disease HBsAg was detected in the serum at least 6 months before the development of acute hepatitis type B, which in each case followed a fulminant course to death. It is suggested that suppression of the normal immunological responses to hepatitis-B viral antigens by cytotoxic drug therapy permitted widespread infection of hepatocytes. Subsequently, upon withdrawal of these drugs, recovery of immunocompetence resulted in rapid destruction of all infected hepatocytes and massive liver damage. Screening for HBsAg before cytotoxic drug therapy, careful monitoring of liver function during its withdrawal, and prompt treatment with corticosteroids should abnormalities occur may prevent this unfortunate sequence of events. Topics: Adult; Antineoplastic Agents; Chlorambucil; Choriocarcinoma; Cyclophosphamide; Dactinomycin; Female; Hepatitis B; Hepatitis B Antigens; Humans; Immunosuppression Therapy; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Male; Mercaptopurine; Methotrexate; Prednisolone; Pregnancy; Substance Withdrawal Syndrome; Vincristine	1975

Article

Year

Unusual skin rash following withdrawal of oral 6-mercaptopurine in children with leukemia.

Medical and pediatric oncology, 1987, Volume: 15, Issue:5

Sixteen episodes of a distinctive, papular rash occurred in eight patients following withdrawal of 6-mercaptopurine (6MP) and methotrexate (MTX) used as maintenance therapy for acute lymphoblastic leukemia (ALL). The rash also developed in one of the eight patients when only 6MP was discontinued. The eruption occurred mainly on the face, and in this site resembled the perioral dermatitis seen following withdrawal of topical fluorinated steroids. The rash generally began within 3 weeks of stopping 6MP and lasted 3 to 4 weeks. It failed to improve with the use of topical corticosteroid. We conclude that this rash is caused by the withdrawal of oral 6MP.

Topics: Child; Face; Female; Humans; Leukemia, Lymphoid; Male; Mercaptopurine; Skin Diseases; Substance Withdrawal Syndrome

1987

Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy.

Lancet (London, England), 1975, Sep-20, Volume: 2, Issue:7934

In three patients with malignant disease HBsAg was detected in the serum at least 6 months before the development of acute hepatitis type B, which in each case followed a fulminant course to death. It is suggested that suppression of the normal immunological responses to hepatitis-B viral antigens by cytotoxic drug therapy permitted widespread infection of hepatocytes. Subsequently, upon withdrawal of these drugs, recovery of immunocompetence resulted in rapid destruction of all infected hepatocytes and massive liver damage. Screening for HBsAg before cytotoxic drug therapy, careful monitoring of liver function during its withdrawal, and prompt treatment with corticosteroids should abnormalities occur may prevent this unfortunate sequence of events.

Topics: Adult; Antineoplastic Agents; Chlorambucil; Choriocarcinoma; Cyclophosphamide; Dactinomycin; Female; Hepatitis B; Hepatitis B Antigens; Humans; Immunosuppression Therapy; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Male; Mercaptopurine; Methotrexate; Prednisolone; Pregnancy; Substance Withdrawal Syndrome; Vincristine

1975